We identified MMR gene mutations (MSH2, MLH1, and PMS2) in three patients (patients 3, 5, and 7), including two IDH wild-type GBM and one IDH-mutant GBM, all of them received systematic TMZ treatment previously, and we did not detect this signature in their tumor tissues. This evidence concerns the gene MSH2 and glioblastoma.